TRIVALENT ION CROSS-LINKED AND ACETALATED GELLAN GUM MICROSPHERES OF GLIMEPIRIDE

  • SUDIPTA DAS Department of Pharmaceutics, Netaji Subhas Chandra Bose Institute of Pharmacy, Chakdaha, West Bengal, India.
  • RIMI DEY Department of Pharmaceutics, Netaji Subhas Chandra Bose Institute of Pharmacy, Chakdaha, West Bengal, India.

Abstract

Objectives: A novel formulation was developed with glimepiride loaded trivalent ion Al+3 cross-linked and acetalated gellan gum microspheres.


Methods: The glimepiride loaded microspheres were formulated using sodium alginate and gellan gum. Cross-linking agents used for the microspheres were aluminum chloride (AlCl3) and glutaraldehyde (GA). The evaluation processes of prepared microspheres were carried out by in-vitro release study, swelling index, microscopic analysis, and entrapment efficiency.


Results: All the formulations show good entrapment efficiency and the maximum entrapment 84.6% was governed by the formulation (F3) cross-linked by AlCl3 and GA and their obtained mean particle size were 12.46±3.21 μm. Release profile of the formulations revealed the sustained design of the drug, particularly this formulation (F3), releasing approximately 40% over 4 h.


Conclusions: From this experiment, it can be accustomed that F3 possesses higher standard formulation than the rest due to good release profile and entrapment efficiency. Therefore, the long term stability study is required for future development of this formulation.

Keywords: Microspheres, Glimepiride, Gellan gum, Drug release

References

1. Chandiran IS, Kumar BP, Jayaveera KN. Design and development of microparticulate drug delivery system of Glimepiride for controlled release. Drug Invent Today 2013;5:235-40.
2. Boni FI, Prezotti FG, Cury BS. Gellan gum microspheres crosslinked with trivalent ion: Effect of polymer and crosslinker concentrations on drug release and mucoadhesive properties. Drug Dev Ind Pharm 2016;42:1283-90.
3. Philip AK, Philip B. Colon targeted drug delivery systems: A review on primary and novel approaches. Oman Med J 2010;25:79-87.
4. Friend DR. Colon-specific drug delivery. Adv Drug Deliv Rev 1991;7:149-99.
5. Carbinatto FM, de Castro AD, Cury BS, Magalhaes A, Evangelista RC. Physical properties of pectin-high amylose starch mixtures cross-linked with sodium trimetaphosphate. Int J Pharm 2012;423:281-8.
6. Meneguin AB, Cury BS, Evangelista RC. Films from resistant starch-pectin dispersions intended for colonic drug delivery. Carbohydr Polym 2014;99:140-9.
7. Osma?ek T, Froelich A, Tasarek S. Application of gellan gum in pharmacy and medicine. Int J Pharm 2014;466:328-40.
8. Tripathi KD. Essentials of Medical Pharmacology. 7th ed. India: Jaypee Brothers Medical Publishers; 2013.
9. Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M, et al. Efficacy of glimepiride in Japanese Type 2 diabetic subjects. Diabetes Res Clin Pract 2005;68:250-7.
10. Morrisa ER, Nishinarib K, Rinaudo M. Gelation of gellan-a review. Food Hydrocoll 2012;28:373-411.
11. Liu Z, Lv D, Liu S, Gong J, Wang D, Xiong M, et al. Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: Effect against breast cancer in mice. PloS One 2013;8:e60190.
12. Maiti S, Ranjit S, Mondol R, Ray S, Sa B. Al+3 ion cross-linked and acetalated gellan hydrogel network beads for prolonged release of glipizide. Carbohydr Polym 2011;85:164-72.
13. Kesharvani S, Jaiswal PK, Mukerjee A, Singh AK. Formulation and evaluation of metformin hydrochloride loaded floating microspheres. Int J Pharm Pharm Sci 2020;12:74-82.
14. Das S, Mondal S. Formulation and in vitro study of ibuprofen loaded cross linked sodium alginate and gellan gum microspheres. Int J Adv Pharm 2017;6:86-90.
15. Lal C, Garg R, Gupta GD. Formulation and optimization by applying 32 full factorial designs of mucoadhesive microspheres of nifedipine. Asian J Pharm Clin Res 2019;12:321-7.
Statistics
21 Views | 22 Downloads
Citatons
How to Cite
DAS, S., and R. DEY. “TRIVALENT ION CROSS-LINKED AND ACETALATED GELLAN GUM MICROSPHERES OF GLIMEPIRIDE”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 13, no. 5, Mar. 2020, pp. 66-68, doi:10.22159/ajpcr.2020.v13i5.37229.
Section
Original Article(s)